The Nelson A. Rockefeller Center for Public Policy and the Social Sciences

Rocky Policy Fellow and Research Assistant Professor Herschel Nachlis published in JAMA

Article Type 

Rocky Policy Fellow and Research Assistant Professor, Herschel Nachlis recently published "Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval" in JAMA, an international peer-reviewed general medical journal.

"In response to the novel coronavirus disease 2019 (COVID-19) crisis, the Food and Drug Administration (FDA), via its Emergency Use Authorization (EUA) authority, initially provided, and then revoked, authorization for use of hydroxychloroquine for treating patients with COVID-19. This process was politically and scientifically contentious and illustrates central problems that can arise with emergency drug authorizations during crises. These problems include the authorization of potentially ineffective or unsafe therapeutics, the appearance of nonexpert political advocacy generating public pressure for product authorizations with questionable safety and efficacy, and the imposition of significant costs on the health of the public and on the credibility and influence of regulatory agencies such as the FDA."

Read the entire article here.

Professor Nachlis was also quoted in the Vox article, Covid-19 vaccine makers are pushing back against pressures to deliver by Election Day.

 

Close
The Nelson A. Rockefeller Center for Public Policy and the Social Sciences